Last updated: about 1 month ago
AstraZeneca's Koselugo Approved: A Breakthrough for NF1 Treatment in Europe!
AstraZeneca's Koselugo gains European approval for adults with NF1, showing 20% efficacy in trials. This marks a significant step in addressing rare disease treatment needs.